Novo Nordisk A/S (NYSE:NVO) Announces Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Novo Nordisk A/S (NYSE:NVO) posted its earnings results on Tuesday. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11, FiscalAI reports. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $2.18 during mid-day trading on Wednesday, hitting $48.12. 18,210,591 shares of the stock traded hands, compared to its average volume of 23,762,275. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company’s 50-day simple moving average is $53.78 and its 200-day simple moving average is $54.18. The firm has a market cap of $214.84 billion, a price-to-earnings ratio of 14.01 and a beta of 0.67.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema (next‑generation diabetes/obesity candidate) delivered strong late‑stage results vs. semaglutide — superior HbA1c and meaningful weight loss, supporting long‑term pipeline value. Read More.
• Positive Sentiment: Q4/2025 earnings beat consensus on EPS and revenue, indicating underlying demand even as guidance disappointed. Read More.
• Positive Sentiment: Novo launched a 2026 share‑buyback programme (overall up to DKK 15bn; immediate programme up to DKK 3.8bn) which supports capital return and offsets dilution from incentive plans. Read More.
• Neutral Sentiment: Management changes: Jamey Millar named head of U.S. business and Hong Chow head of product & portfolio strategy — operational moves that could matter for U.S. execution. Read More.
• Negative Sentiment: Guidance shock: Novo forecast adjusted sales and operating profit declines of roughly 5%–13% in 2026 (constant FX), citing lower realized prices, U.S. price cuts and loss of exclusivity — the primary driver of today’s selloff. Read More.
• Negative Sentiment: CEO warnings and pricing pressure: Management described U.S. Wegovy price reductions as “painful” and warned investors that performance may get worse before improving, signaling sustained margin and topline pressure. Read More.
• Negative Sentiment: Competitive risk rising: Pfizer reported monthly GLP‑1 data (Metsera) with weight‑loss outcomes comparable to peers, intensifying pricing and market‑share competition in obesity medicines. Read More.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NVO. Johnson Financial Group Inc. increased its position in shares of Novo Nordisk A/S by 128.0% in the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after acquiring an additional 384 shares in the last quarter. State of Wyoming grew its position in Novo Nordisk A/S by 72.7% during the 2nd quarter. State of Wyoming now owns 950 shares of the company’s stock worth $66,000 after purchasing an additional 400 shares in the last quarter. Binnacle Investments Inc raised its stake in Novo Nordisk A/S by 126.2% during the 2nd quarter. Binnacle Investments Inc now owns 1,190 shares of the company’s stock valued at $82,000 after purchasing an additional 664 shares during the period. Palisade Asset Management LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $110,000. Finally, Newbridge Financial Services Group Inc. grew its holdings in shares of Novo Nordisk A/S by 717.9% during the third quarter. Newbridge Financial Services Group Inc. now owns 2,102 shares of the company’s stock valued at $117,000 after buying an additional 1,845 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on NVO. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Finally, BMO Capital Markets set a $57.00 price target on Novo Nordisk A/S in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.